Xsensio SA Raises $7 Million in Oversubscribed Series A Funding
Share this article
Xsensio SA, a Vaud-based high-tech company pioneering continuous biochemical monitoring in near real time, announced the closing of a Series A funding round with an oversubscription of $7 million. The round was led by San Francisco-based venture capital firm WI Harper, with participation from Privilège Ventures, the European Innovation Council and private investors from the United States, Europe and Asia.
Xsensio’s Lab-on-Skin© wearable biosensing device, is enabling the simultaneous, continuous monitoring of multiple biochemical biomarkers.
This new funding will enable Xsensio to accelerate the development and clinical validation of its Lab-on-Skin© wearable biosensing platform, designed to provide dynamic, multimodal biochemical information to aid clinical decision-making in hospitals and elsewhere.
‘This Series A marks a crucial step in the implementation of continuous biochemical monitoring in real clinical environments,’ said Esmeralda Megally, CEO of Xsensio. ” For the first time, clinicians can access key, continuous biochemical data in real time, information that was previously unavailable at the point of care. This capability has the potential to fundamentally improve the way patients are monitored and treated.”
At the same time, Xsensio announced a long-term collaboration with Texas Instruments, a global leader in semiconductor technology. This collaboration brings unique expertise in CMOS integration, miniaturisation and large-scale manufacturing of biosensing systems, further strengthening Xsensio’s industrial scalability.
‘Our collaboration with Texas Instruments significantly strengthens our path to advanced and scalable semiconductor technology,’ added Adrian Ionescu, Chief Technology Officer at Xsensio. “By combining our biosensing innovation with world-class semiconductor expertise, we are building a platform designed not only to have clinical impact, but also to be deployed reliably and cost-effectively. “
‘We believe Xsensio is defining a new category of wearable biosensing. Given the company’s strong progress and commercial potential, we are delighted to lead this investment round,’ said Wilson Wu, Partner at WI Harper.
‘Continuous biochemical monitoring represents a major shift from intermittent measurements to real-time information, and Xsensio is uniquely positioned to lead this transformation,’ said Jaqueline Ruedin Rüsch, Chair of the Board of Directors.
About Xsensio
Xsensio is a Swiss high-tech company developing the Lab-on-Skin© portable biosensing platform to provide continuous, real-time biochemical information for personalised and preventive healthcare. Emerging from cutting-edge university research, the company collaborates with leading hospitals and industrial partners to bring clinically meaningful biosensing innovations to patients in hospitals and beyond. Xsensio has been recognised by TIME as one of the world’s best companies in the field of health technologies in 2025.